

UCLA

UCLA Previously Published Works

Title

Mutations in DYNC2LI1 disrupt cilia function and cause short rib polydactyly syndrome

Permalink

<https://escholarship.org/uc/item/4nd2x1gp>

Journal

Nature Communications, 6(1)

ISSN

2041-1723

Authors

Taylor, S Paige

Dantas, Tiago J

Duran, Ivan

et al.

Publication Date

2015

DOI

10.1038/ncomms8092

Peer reviewed



Published in final edited form as:

Nat Commun. ; 6: 7092. doi:10.1038/ncomms8092.

Mutations in *DYNC2LI1* disrupt cilia function and cause short rib polydactyly syndrome

S. Paige Taylor^{1,*}, Tiago J. Dantas^{2,*}, Ivan Duran³, Sulin Wu³, Ralph S. Lachman⁴, University of Washington Center for Mendelian Genomics⁵, Stanley F. Nelson^{1,6}, Daniel H. Cohn^{3,4,7}, Richard B. Vallee², and Deborah Krakow^{1,3,4,8}

¹Department of Human Genetics, University of California Los Angeles, Los Angeles, California, USA, 90095

²Department of Pathology and Cell Biology, Columbia University, New York, USA, 10032

³Department of Orthopaedic Surgery and Orthopaedic Institute for Children, University of California Los Angeles, Los Angeles, California, USA, 90095

⁴International Skeletal Dysplasia Registry, University of California Los Angeles, Los Angeles, California, USA, 90095

⁵University of Washington Center for Mendelian Genomics, University of Washington, Seattle, Washington, USA, 98195

⁶Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, USA, 90095

⁷Department of Molecular, Cell, and Developmental Biology, University of California Los Angeles, Los Angeles, California, USA, 90095

Abstract

The short rib polydactyly syndromes (SRPS) are a heterogeneous group of autosomal recessive, perinatal-lethal skeletal disorders characterized primarily by short, horizontal ribs, short limbs, and poly-dactyly. Mutations in several genes affecting intraflagellar transport (IFT) cause SRPS but

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

⁸Correspondence should be addressed to D.K. (DKrakow@mednet.ucla.edu).

*These authors contributed equally to this manuscript

Author contributions

S.P.T., D.C and D.K. conceived of the study and S.P.T., T.D. and D.K. wrote the manuscript. R.L., D.C., and D.K. defined radiographic features and identified the SRPS phenotype. S.P.T., T.D., D.K., and R.V. designed and supervised experiments and were involved in data interpretation. U.W.C.M.G. and S.F.N. provided whole exome sequencing data and S.P.T. and S.W. performed whole-exome sequencing analysis. S.P.T. and T.D. performed Hedgehog stimulation experiments, Western blots, RT-PCR and immunofluorescence analysis of human fibroblasts. I.D. performed immunohistochemistry of human cartilage growth plate and qPCR experiments. S.P.T. performed Sanger sequencing of human samples. T.D. performed ciliary and IFT measurements, RNAi knockdown and rescue experiments on patient fibroblasts. D.K. was involved in patient enrollment. S.F.N. provided computational infrastructure for data processing.

Competing Financial Interests

The authors have no competing interests.

ACCESSION CODES

The sequence data have been deposited in ClinVar under the accession codes SCV000212251, SCV000212252, SCV000212253, SCV000212254, SCV000212255 and SCV000212256.

they do not account for all cases. Here we identify additional SRPS genes and further unravel the functional basis for IFT. We perform whole exome sequencing and identify mutations in a new disease-producing gene, cytoplasmic dynein-2 light intermediate chain 1, *DYNC2LI1*, segregating with disease in three families. Using primary fibroblasts, we show that *DYNC2LI1* is essential for dynein-2 complex stability and that mutations in *DYNC2LI1* result in variable-length, including hyperelongated, cilia, Hedgehog pathway impairment, and ciliary IFT accumulations. The findings in this study expand our understanding of SRPS locus heterogeneity and demonstrate the importance of *DYNC2LI1* in dynein-2 complex stability, cilium function, Hedgehog regulation, and skeletogenesis.

Introduction

The primary cilium is a microtubule-based projection on the surface of nearly every cell that acts as a concentrated signaling center for several pathways¹. Defects in the formation or function of primary cilia cause a wide variety of disorders known as ciliopathies. As a testament to the importance of this organelle, ciliopathies collectively affect all major organ systems², including the skeleton. Cilium assembly and function require intraflagellar transport (IFT), a system for bidirectional traffic into and out of this organelle. IFT depends on the microtubule motor protein activities of two multi-protein complexes³: IFT-B, the kinesin-2-driven anterograde complex, mediates base-to-tip transport, and IFT-A, the dynein-2-driven retrograde complex, mediates tip-to-base transport.

The SRPS are autosomal recessive, perinatal-lethal disorders. Radiographic abnormalities include very short, horizontal ribs, short limbs, and variable degrees of polydactyly. Other organ system abnormalities, particularly those affecting the heart and kidney, are frequently seen. SRPS are part of a spectrum of heterogeneous skeletal ciliopathies that include Asphyxiating Thoracic Dystrophy (ATD), Ellis van Creveld and Sensenbrenner syndromes. Mutations in the gene encoding the IFT-A cytoplasmic dynein-2 motor heavy chain, *DYNC2H1* (MIM 603297), are the most common cause of both SRPS and ATD^{4, 5}. Recently, mutations in several additional genes have been shown to cause SRPS: *IFT80*^{6, 7} (MIM 611263), *WDR35*^{8, 9} (MIM 614091), *WDR19*¹⁰ (MIM 614376), *NEK1*^{11, 12} (MIM 263520), *WDR34*^{13, 14} (MIM 615633), *IFT140*^{15, 16} (MIM 266920), *IFT172*¹⁷ (MIM 615630), *WDR60*¹⁸ (MIM 615462), and *TTC21B*¹⁹ (MIM 612014). Among the proteins encoded by the SRPS genes, *WDR60* and *WDR34* are intermediate chains of the *DYNC2H1* cytoplasmic dynein-2 complex, highlighting its importance in skeletal development²⁰. Here we show that mutations in another member of the complex, *DYNC2LI1*, also cause SRPS, in part through loss of complex stability.

The IFT-A dynein-2 complex is composed of at least five components: the dynein heavy chain *DYNC2H1* (DHC1b)^{21, 22, 23}, the two intermediate chains *WDR34* (DIC5/FAP133)²⁴ and *WDR60* (FAP153)²⁵, the light intermediate chain *DYNC2LI1* (D1bLIC/D2LIC/LIC3/XBX1)^{26, 27, 28, 29} and the LC8 light chain³⁰. *DYNC2LI1* was described as a novel dynein light intermediate chain based on its amino acid sequence, its ability to interact with *DYNC2H1*, and its localization to cilia^{26, 31}. As an accessory chain binding to the base of the dynein-2 complex, *DYNC2LI1* is likely involved in tethering the dynein-2 motor to

substrates such as vesicles and providing docking sites for cargo^{26, 31}. It is essential for cilio-genesis and contains an X-box promoter that is recognized by the ciliary transcription factor RFX3/DAF-19^{28, 32}. Recent studies have shown that *DYNC2LI1* is essential for dynein-2 complex stability and its depletion in *Trypanosoma brucei* and *Chlamydomonas reinhardtii* results in loss and mislocalization of *DYNC2H1*^{24, 29, 33, 34}. Furthermore, *DYNC2LI1* mouse mutants result in lethality early in embryogenesis with developmental abnormalities characteristic of severe Hedgehog signaling defects³⁵.

In this study, we identify mutations in *DYNC2LI1* causing SRPS in three independent cases. We show that *DYNC2LI1* is essential for dynein-2 complex stability, is expressed in the cartilage growth plate, and plays critical roles in the regulation of primary cilium length, retrograde IFT, and Hedgehog signaling. Analysis of SRPS-derived fibroblasts supports a role for *DYNC2LI1* in cilia function and signaling and the findings highlight the importance of this gene and the dynein-2 complex in skeletogenesis.

Results

DYNC2LI1 mutations identified in SRPS cases

To identify additional genes that are essential for skeletal development, we used whole exome sequencing under an approved human subjects protocol and identified mutations in the dynein-2 light intermediate chain gene, *DYNC2LI1*, producing SRPS. Three probands from unrelated Caucasian families were identified by prenatal ultrasound and elective terminations were performed at 14, 19, and 22 weeks, respectively. In the prenatal period, ultrasound findings included shortened long bones, diminished chest circumferences for gestational age, and polydactyly. No other obvious organ system abnormalities were detected by ultrasound. Radiographic analyses showed polydactyly of the upper and lower extremities, a long narrow thorax with very short horizontal ribs, lack of ossification of some skeletal elements, and irregular metaphyseal borders with lateral spikes (Fig. 1). These findings are characteristic of SRPS and radiographically similar to SRPS cases described with *DYNC2H1* and *WDR34* mutations^{4, 13, 36}.

In all three cases there was compound heterozygosity for mutations in *DYNC2LI1* (Supplementary Fig. 1). Two affected individuals, R01-013A and R03-303A, were heterozygous for changes in in-tron 12 (c.993+1G>A, c.993+3A>G) that are predicted to affect splicing (Table 1). RT-PCR analysis on RNA derived from fibroblasts from both fetuses demonstrated that both mutations resulted in in-frame skipping of exon 12 (Fig. 2a). R01-013A and R07-628A were both heterozygous for a point mutation causing the predicted amino acid p.Leu117Val substitution. This missense mutation occurs within a region conserved among the three mammalian dynein light intermediate chains (DLICs) and resides within an NTPase-related domain (Supplementary Fig. 2). This mutation may interfere with cargo-binding as it occurs within a homologous region that is required for cargo-binding in *DYNC1LI1*³⁷. However, of the three mammalian DLICs, only *DYNC2LI1* interacts with the dynein-2 complex; the more closely related *DYNC1LI1* and *DYNC1LI2* are targeted to the non-ciliary cytoplasmic dynein-1, *DYNC1H1*^{26, 38}. Finally, the other heterozygous changes in R07-628A and R03-303A were nonsense mutations in exon 6 (p.Trp124Ter) and 13 (p.Glu334Ter), respectively. Western blot analyses of fibroblast-derived lysates showed that

DYNC2LI1 is markedly reduced in R01-013A (c.993+1G>A; p.Leu117Val) and R07-628A (p.Trp124Ter; p.Leu117Val), indicating that these mutations likely lead to loss of DYNC2LI1 stability (Fig. 2b,c).

DYNC2LI1-mutant fibroblasts are depleted of DYNC2H1

DYNC2H1 and DYNC2LI1 are distinct components of the ciliary dynein-2 complex and studies in *Chlamydomonas reinhardtii* and *Trypanosoma brucei* show that loss of one results in loss or reduction of the other^{24, 29, 33, 34}. To determine whether DYNC2H1 amounts were affected by the decrease in DYNC2LI1, we probed whole-cell lysates from SRPS cases and controls for DYNC2H1 and discovered near-total loss of protein (Fig. 3a). The amounts of the dynein-2 intermediate chain WDR34 and the heavy chain of the dynein-1 complex (DYNC1H1) were unchanged, indicating that the effects of the *DYNC2LI1* mutations were specific to DYNC2H1. Immunofluorescence staining showed that WDR34 and the minimal remaining DYNC2H1 in SRPS cells localized to the basal bodies, similar to controls (Fig. 3b). These results suggest that even though DYNC2LI1 is important for the stabilization of DYNC2H1, it is not essential for the recruitment of the dynein-2 complex to the pericentriolar region of basal bodies.

DYNC2LI1 is expressed in the developing human growth plate

While the dynein-2 complex is required for IFT in all ciliated cells of the body, the marked skeletal consequences of dynein-2 complex mutations suggest that the developing skeleton is very sensitive to reductions in its activity. Concordant with this hypothesis, transcriptional analysis by qRT-PCR showed that *DYNC2LI1* was more highly expressed in bone compared with other embryonic tissues (bone, brain, cartilage, heart, liver, lung, placenta and thymus) (Supplementary Fig. 3). Furthermore, immunohistochemistry of human cartilage growth plate revealed DYNC2LI1 expression in the perichondrium, periosteum and primary spongiosa of bone (Fig. 4). Similarly, immunohistochemistry of DYNC2H1 and WDR34 showed an overlapping expression pattern (Fig. 4). Together, these expression studies support a role for DYNC2LI1 and the dynein-2 complex in human skeletal development.

SRPS fibroblasts exhibit loss of ciliary length control

To investigate whether mutations in *DYNC2LI1* affect ciliogenesis and/or IFT, we quantified the fraction of ciliated cells, measured cilia length and probed SRPS and control fibroblasts for a number of ciliary components. The percentage of ciliated cells was only slightly reduced between SRPS and control cells (Fig. 5b). However, we found that primary cilia length was highly variable in SRPS fibroblasts, with a substantial increase in the number of hyperelongated cilia up to 20 μm in length (Fig. 5a,c,d). To determine if the ciliary length variation observed in SRPS cells resulted from decreased amounts of DYNC2LI1, we performed RNAi against *DYNC2LI1* in hTERT-RPE1 (retinal epithelial) cells. *DYNC2LI1*-knockdown led to significantly increased variation in cilia length, thus reproducing the phenotype observed in SRPS fibroblasts (Supplementary Fig. 4a,b). To test for phenotypic rescue, we expressed wild type *DYNC2LI1* in SRPS cells. As shown in Fig. 5c,d, transfection of *DYNC2LI1* into SRPS fibroblasts reduced ciliary length variation and

restored length to control values. We therefore conclude that *DYNC2LI1* and the dynein-2 complex play an important role in the regulation of primary cilia length.

IFT components accumulate in *DYNC2LI1*-mutant cilia

The IFT-B components, IFT88 and TRAF3IP1, and the IFT-B kinesin motor, KIF3A, localized strongly to the base of the cilia and weakly along the axoneme in control cells, as observed by others³⁹ (Fig. 6a). Consistent with defective retrograde transport in SRPS fibroblasts, IFT88, TRAF3IP1, and KIF3A all accumulated near the cilia tip. More specifically, three to four fold more IFT88 was retained in the axonemes of *DYNC2LI1*-mutant cilia than in controls (Fig 6c). RNAi-knockdown of *DYNC2LI1* in RPE1 cells replicated this finding by increasing the ratio of IFT88 retained in the primary cilium body relative to the proximal end by three fold (Supplementary Fig. 4c,d). In addition, we were able to reduce this ratio in SRPS fibroblasts by expressing wild type *DYNC2LI1* (Fig. 6b,c). Our results demonstrate that loss of *DYNC2LI1* markedly impairs retrograde IFT and leads to the accumulation of IFT proteins within the primary cilium.

SMO inappropriately enters the cilia of SRPS fibroblasts

Hedgehog signaling requires intact cilia and IFT; not surprisingly, many IFT mutants display defects in this pathway⁴⁰. To determine if *DYNC2LI1* mutations affect Hedgehog signaling, we examined the localization of SMO and GLI3 in SMO agonist (SAG)-stimulated and unstimulated fibroblasts from SRPS cases and controls. While the localization of GLI3 did not differ between SRPS and control cells (Fig. 7a), we detected SMO along the length of cilia of unstimulated *DYNC2LI1*-mutant cells (Fig. 7b,c). In contrast, SMO was only observed in the cilia of control cells upon stimulation. Similar to findings in *DYNC2H1* mouse mutants⁴¹, these observations suggest that *DYNC2LI1* and the activity of the dynein-2 complex play an important role in preventing SMO from entering cilia in the absence of Hedgehog stimulation.

DYNC2LI1 mutants exhibit reduced GLI3 processing

To further investigate Hedgehog pathway activation, we measured GLI3 processing in affected and control fibroblasts stimulated with SAG and quantified the ratio of GLI3 full-length (GLI3FL) to re-pressor (GLI3R) forms by Western blot analysis. We found that this ratio is increased two to three fold in *DYNC2LI1*-mutant fibroblasts as compared with control cells (Fig. 7d,e). An increased ratio of GLI3FL to GLI3R suggests impaired proteolytic processing of GLI3, which has been proposed to be the underlying cause for the polydactyly commonly seen in SRPS and other ciliopathies⁴². In addition, total GLI3 was markedly increased in unstimulated *DYNC2LI1*-mutant fibroblasts, implying that not only is processing altered but the total amount of available GLI3 is abnormal as well (Fig. 7d,f). To test whether this altered ratio had functional consequences on transcription of Hedgehog targets, we performed quantitative RT-PCR of *PTCH1* and *GLI1* on control and SRPS fibroblasts. We found that both control and SRPS cells responded to SAG with an increase in *PTCH1* and *GLI1* cDNA (Supplementary Fig. 5), suggesting that in these cells, the loss of the dynein-2 complex stability does not completely impair their ability to respond to SAG. Yet, altered GLI3FL to GLI3R ratios, together with the abnormal distribution of SMO into

cilia of unstimulated SRPS cells, support impaired regulation of Hedgehog signaling in cells from SRPS cases with *DYNC2L1* mutations.

Discussion

We show that *DYNC2L1* mutations cause SRPS, expanding the number of genes associated with this condition. The phenotypic findings in these SRPS cases are similar to those seen in cases with *DYNC2H1*³⁶ and *WDR34*¹³ mutations, supporting that these proteins are part of the same complex. Using SRPS fibroblasts we show that *DYNC2L1* mutations result in loss of cilia length regulation, ciliary accumulation of IFT components, and aberrant Hedgehog pathway activity. Rescue of mutant fibroblasts with human *DYNC2L1* corrected the cilia phenotype, directly confirming that the changes in cilia length and IFT resulted from the loss of normal *DYNC2L1*.

Our findings demonstrate that *DYNC2L1* is involved in both the repression of Hedgehog activity in the absence of stimulation and the activation of Hedgehog in response to stimulation. Alterations to Hedgehog signaling due to mutations in IFT-A proteins are typically mediated by either changes in cilia structure or trafficking, as opposed to non-ciliary functions of these proteins⁴³. In the absence of stimulation, SMO is actively excluded from the cilia and *GLI3* is processed into its repressor form. We show that SMO inappropriately enters the cilium in the absence of SAG stimulation in SRPS but not in control cells (Fig. 7b). This abnormal ciliary localization of SMO has been seen in other IFT mutants as well, including *DYNC2H1*⁴¹ and *ICK*⁴⁴, and is suggestive of inappropriate Hedgehog pathway activation. Whether this SMO is active or not remains to be determined, however the deficient processing of *GLI3* into the repressor form suggests the former in *DYNC2L1*-mutant fibroblasts (Fig. 7d,e). We observed that *DYNC2L1*-mutant SRPS cells exhibit increased amounts of *GLI3FL* with and without stimulation, increased ratios of *GLI3FL* to *GLI3R*, and decreased amounts of *GLI3R* upon stimulation as compared with controls. However, we could not identify a grossly abnormal transcriptional response in SRPS cells. This suggests that these cells can at least partially respond to Hedgehog signaling, though the *in-vivo* consequences of persistent altered *GLI3FL* to *GLI3R* amounts in certain tissues, particularly in a temporal manner, may underlie developmental abnormalities, particularly polydactyly, as seen in these SRPS cases.

We found that mutations in *DYNC2L1* do not preclude cilia formation, but rather cause cilia length dysregulation. Based on the phenotype of most mutants with diminished capacities for retrograde transport, including dynein-2 complex mutants, it is interesting that cilia in *DYNC2L1* mutants are longer than those in controls. In *Chlamydomonas*, dynein-2 null mutants (*dhc1b*²¹; *stf-1*, *stf-2*²²) have short, bulbous cilia with an accumulation of IFT-B components at their tips, suggesting an essential role for dynein-2 in recycling ciliary components back to the cell body. As IFT-B accumulates in these mutants, exhausting the pool of kinesin-2, the cilium loses its ability to grow or even maintain its length. In contrast, the *DYNC2L1*-mutant SRPS cases reported here have pronounced losses of both *DYNC2H1* and *DYNC2L1* yet display robust ciliogenesis with longer-than-average cilia, despite having the characteristic IFT-B accumulations. This is similar to dynein-2 mutants in *Tetrahymena* (KO-D2LIC)⁴⁵. It is thus likely that the *DYNC2L1* mutations alter the

functioning of the dynein-2 complex without abolishing function altogether. The main defect in these cells appears to be loss of cilia length regulation as is evidenced by large variations in cilia lengths. It is possible that the small amount of remaining normal DYNC2H1 is enough to prevent the IFT congestion and stunted cilia seen in other mutants⁴⁶. We therefore conclude that the residual activity of the dynein-2 complex in *DYNC2L11*-mutant fibroblasts was enough to support robust ciliogenesis but insufficient to ensure the correct regulation of primary cilium size.

While we have shown that mutations in *DYNC2L11* produce a severe skeletal dysplasia, little is known regarding the expression of this gene in distinct tissues. Quantitative RT-PCR from RNA derived from a series of 16-week fetal tissues showed that *DYNC2L11* is expressed in all tissues studied, but is highest in bone (Supplementary Fig. 3). Furthermore, the dynein-2 complex proteins we evaluated localized to the perichondrium/periosteum and primary spongiosa of bone (Fig. 4), suggesting an important role in the developing skeleton. These regions have been shown to be important for signaling and organization of a normal cartilage growth plate^{47, 48}. The primary spongiosa, in particular, was reported to be irregular in SRPS cases with *DYNC2H1* mutations⁴ with loss of degradation of the mineralized hypertrophic zone, supporting the potential role of the dynein-2 complex in orchestrating the development of normal endochondral bone formation. Localization of the dynein-2 complex to the cartilage growth plate begins to provide insight into the reasons for altered endochondral ossification that are seen in SRPS.

In summary, our findings establish the clinical and cellular consequences of *DYNC2L11* mutations and dynein-2 complex disruption in human primary cells, and support the profound importance of this protein complex in proper skeletogenesis.

Methods

Exome sequencing

Under an approved University of California at Los Angeles human subjects protocol, DNA was isolated and submitted to the University of Washington Center for Mendelian Genomics for library preparation and exome sequencing. The samples were barcoded, captured using the NimbleGen SeqCap EZ Exome Library v2.0 probe library targeting 36.5Mb of genome, and sequenced on the Illumina GAIIx platform with 50 bp reads. Novoalign was used to align the sequencing data to the human reference genome [NCBI build 37] and the Genome Analysis Toolkit (GATK)⁴⁹ was used for post-processing and variant calling according to GATK Best Practices recommendations^{50, 51}. Average coverage of targeted bases was 103X, 61X, and 56X for R01-013A, R07-627A, and R03-303A, respectively. For each sample, at least 90% of targeted bases were covered by at least 10 independent reads. Variants were filtered against dbSNP137, 95 NIEHS EGP exome samples (v.0.0.8), 6503 exomes from the NHLBI Exome Sequencing Project (ESP6500), 1000 genomes (release 3.20120430), and 40 in-house exome samples. Mutations were further compared with known disease-causing mutations in HGMD (2012.2). Variants were annotated using VAX⁵² and mutation pathogenicity was predicted using the programs Polyphen⁵³, Sift⁵⁴, Condel⁵⁵, and CADD⁵⁶. The mutations reported in this work were confirmed by

bidirectional Sanger sequencing of amplified DNA from the proband and available parents (Supplementary Fig. 1). Primer sequences used were:

DYNC2L1-ex6 F': TTTTGT TTTTGGGAGTCTTAGAA
R': TTGCTGTAATTTTCCAGTGAACA

DYNC2L1-ex12 F': ACCTGGCAGAATTGGAAGTG R':
GGTGGGATGACAGGTGATTT

DYNC2L1-ex13 F': GTGCTGCTTAGCCACACAGA R':
GTGGGCACTTAACCTTGCAT

Sequence trace files were aligned and analyzed using Geneious version 7.1.4 created by Biomatters (<http://www.geneious.com/>).

The samples were part of a larger cohort of SRPS samples submitted for the purpose of identifying novel disease genes and characterizing the incidence of mutations in known genes. The cohort had not been previously tested for mutations in known SRPS-causing genes.

Filtering Strategy

We prioritized mutations predicted to affect protein function (insertions or deletions, frameshifts, non-synonymous mutations, and essential splice site mutations). We later included highly conserved splice region variants, allowing us to discover the *DYNC2L1* +3 splice site mutation. We prioritized mutations that had not been previously seen in the homozygous state in control databases and mutations with a minor allele frequency < 0.005. Due to the recessive inheritance of SRPS, we looked for genes in which both alleles were potentially mutated. *DYNC2L1* stood out as a potential gene due to the incidence of unique, compound heterozygous mutations in three families in which the SRPS cases had strikingly similar X-ray features.

RT-PCR

RNA from SRPS case and control fibroblast cell lines was extracted using TRIZOL (Invitrogen 15596). RT-PCR was performed using SuperScript III One Step Kit (Invitrogen 12574-018) with the following *DYNC2L1* primers targeting a 431 bp template spanning exon 12: F': CGCTGTTTATCACAGCAGGA R': CCAAGAAATCCAGCTTGTCC. An amplified fragment of 431 bp corresponds to the wild-type RNA and a fragment of 339 bp corresponds to a transcript missing exon 12.

Quantitative RT-PCR

Total RNA was extracted from a series of 16-week fetal tissues as well as from control, R01-013A and R07-628A fibroblasts (with and without SAG treatment) using TRIZOL (Invitrogen 15596). cDNA was treated with DNAase (Invitrogen 18068) and reversed transcribed (Thermo Scientific K1621) according to the manufacturer's instructions. Quantitative RT-PCR was performed with a real-time PCR detection system (Stratagene MX3005P) using SYBR green PCR master mix (Thermo Scientific K0222) and standard thermocycler conditions. qRT-PCRs were performed in triplicate in a total volume of 25 μ l

for 3 independent replicates. Each sample was analyzed for two housekeeping genes to normalize for RNA input amounts and to perform relative quantifications. Levels of transcripts in controls were set at 1. Melting curve analysis showed a single, sharp peak with the expected melting temperature for all samples. RT-PCR primers sequences were as follows:

DYNC2LI1 F': GAAGGTGATGGAGCTGAAATTG	R': GTATATTCCAAAGCTAAGGTTGGTT
YWHAZ F': CAGCAGATGGCTCGAGAATA	R': GAAGCATTGGGGATCAAGAA
BACT F': TCCCTGGAGAAGAGCTACGA	R': AGGAAGGAAGGCTGGAAGAG
PTCH1 F': ACTCTGCTGGGAGTGCTGAT	R': AAAACCAGCCCATTGAGAAC
GLI1 F': ACACCGGTACCACTGTGTCC	R': CGGCTGACAGTATAGGCAGA
GAPDH F': CGTAGCTCAGGCCTCAAGAC	R': GCTGCGGGCTCAATTTATAG
GUSB F': CGAATCACTATCGCCATCAA	R': CCCTGGGATACTTGGAGGT

Molecular cloning of *DYNC2LI1*

Human *DYNC2LI1* cDNA (NM_016008.3) was synthesized using gBlock from IDT. The cDNA was flanked by XhoI and NotI restriction sites, which were used for insertion into pCAGIG, a pCAG-IRES-GFP vector (a gift from Connie Cepko (Addgene plasmid #11159)). The final construct was then used to express both untagged *DYNC2LI1* and GFP in SRPS fibroblasts for the rescue experiments.

Cell culture

Unless otherwise stated, control and SRPS human fibroblasts from patients were grown in DMEM supplemented with 10% FBS, 1% Penicillin/Streptomycin/L-Glutamine and were maintained at 37°C with 5% CO₂.

For serum starvation and to promote ciliogenesis, cells were washed in PBS and incubated with serum-free media (or supplemented with 0.5% FBS) for 48 hrs. For stimulation of the sonic hedgehog pathway, serum-free media was supplemented with 500 nM SAG (Calbiochem 566660) for 24–48 hrs before cell fixation. hTERT-RPE1-GFP-CSAP cells (a kind gift from I. Cheeseman)⁵⁷ were grown in DMEM/F12 supplemented with 10% FBS, 1% Penicillin/Streptomycin and were maintained at 37°C with 5% CO₂.

Rescue experiments

Transfections of SRPS fibroblasts with h*DYNC2LI1* IRES GFP were performed using Amaxa Kit for Primary Mammalian Fibroblasts according to manufacturer's instructions and program T-16. 24 hrs following transfection, cells were washed in PBS and incubated with serum-free media for an additional 48 hrs.

RNAi

For RNA-mediated interference, siGENOME (51626) Human *DYNC2LI1* siRNA smartpool (Dharma-con) was employed against the following target sequences:

5'-GGAAUAAUAUGCCGAAGGA-3'

5'-CAAAAGAUAU CGCUCACUU-3'

5'-CCAUGUAGACAAAGUGAUA-3'

5'-GGAAAGACUACUAUUAUUC-3'.

Non-targeting siRNA was used as a control. RNAi was carried out using the Hiperfect reagent (Qiagen), according to manufacturer's instructions. 48 hrs following RNAi transfection, hTERT-RPE1-GFP-CSAP cells⁵⁷ (RPE1 cells with ciliary axoneme and centrioles marked by CSAP) were washed in PBS and incubated with an additional round of RNAi in serum-free media for 48 hrs to induce ciliogenesis. Knockdown was confirmed by Western blotting.

Immunofluorescence—Cells were seeded into 4-well chamber slides (LabTek) at a density of 4×10^4 cells per well and allowed to adhere overnight. After serum starvation, cells were washed twice with PBS and fixed in 95% methanol with 5 mM EGTA (pre-chilled to -20°C) for 5 min. Alternatively, cells were fixed in 4% PFA for 15 min at room temperature, washed, and then permeabilized with 0.1% Triton-X-100 in PBS for 5 min at room temperature. After extensive washing, cells were blocked in PBS containing 5% serum for 1 hr at room temperature. Primary antibodies were diluted in PBS containing 1–5% serum. Cells were incubated with the following primary antibodies for 1 hr at room temperature or overnight at 4°C : rabbit anti-WDR34 (1:200; Abcam ab81030), rabbit anti-DYNC2H1²⁶ (1:150; Dynein HC2), rabbit anti-ARL13B (1:150; Proteintech 17711-1-AP), rabbit anti-IFT88 (1:150; Proteintech 13967-1-AP), rabbit anti-KIF3A (1:150; Sigma-Aldrich K3513), rabbit anti-TRAF3IP1 (1:100; Pierce PA5-30507), mouse anti-acetylated β -tubulin (1:2,000; 6-11B-1; Sigma-Aldrich T6793), rabbit anti-acetylated β -tubulin (1:800; D20G3; Cell Signaling Technology #5335), mouse anti-polyglutamylated tubulin (GluTUB) (1:300; Adipogen GT335), SMO (1:300; a kind gift from K. Anderson), and goat anti-GLI3 ($10 \mu\text{g mL}^{-1}$; R&D Systems AF3690). After extensive washing, cells were incubated for 1 hr at room temperature with Alexa Fluor 488/ 568-conjugated secondary antibodies (1:400; Invitrogen and Jackson ImmunoResearch) in PBS containing 5% serum. For rescue experiments in Figs. 5d and 6b, Cy5- and Cy3-labeled secondary antibodies (1:400; Jackson ImmunoResearch) were used to detect ARL13B/IFT88 and GluTUB, respectively. Images were captured on an IX80 laser scanning confocal microscope (Olympus FV100 Spectral Confocal System) or a Leica Confocal TCS-SP2 using a 100x 1.40 N.A. or a 63X (oil) objective 1.2 N.A. Images were collected with 1024x1024 pixel definition and Z-sections were taken at 0.5 μm step size. Max projections of the Z-stacks were used for primary cilium measurement and counting in ImageJ (NIH). To assess the impact of *DYNC2L1* mutations on ciliogenesis, we examined the localization of the ciliary membrane and axoneme markers ARL13B and glutamylated tubulin. ARL13B is a membrane protein belonging to the Arf family of GTPases that constitutively localizes to cilia. ARL13B signal is dispersed in the cytoplasm if a cell does not have a cilium, which allowed us to confidently score the percentage of ciliated cells when co-staining with an axonemal marker. Tubulin acetylation and glu-tamylation⁵⁸ are post-translational modifications associated with stable microtubule structures such as the cilia axoneme and, for glutamylated tubulin, the basal body and other centrioles.

Quantification of IFT88 retention in the distal end of primary cilia was performed in similar-sized primary cilia using ImageJ (NIH). Polyglutamylated tubulin staining of centrioles and the proximal end of the axoneme served to determine the orientation of each primary cilium, allowing for the measurement of IFT88 signal intensity in the proximal end and in the remaining body of each primary cilium. After determining the ratio of IFT88 signal in each primary cilium, the resulting values were used to determine the average ratio of IFT88 signal for each experiment. Statistical analyses were performed with Prism v 5.0 (GraphPad).

Immunohistochemistry

A human humerus from a 14-week fetus was fixed in PFA and decalcified with Immunocal for 2 days. After decalcification, samples were embedded in paraffin and 10 μm sections were prepared. Sections were treated with citrate buffer for antigen retrieval and quenched by peroxidase solution for 10 min each. Primary antibodies used were: rabbit anti-DYNC2LI1²⁶ (1:200; LIC3), rabbit anti-WDR34 (1:150; Sigma HPA041091) and rabbit anti-DYNC2H1²⁶ (1:150; Dynein HC2). After primary incubation, a Histostain Plus kit (Invitrogen 85-9243) was used for development with DAB.

Protein/Western blot analysis

Cells were lysed in 1X RIPA Buffer (Cell Signaling Technology) supplemented with 1 mM PMSF and a protease inhibitor cocktail (Sigma-Aldrich). Lysates were cleared by centrifugation (10 min at 16,000 \times g at 4°C). 20–80 μg of protein per sample was loaded onto 10% or gradient SDS-polyacrylamide gels and separated by electrophoresis. Proteins were transferred to PVDF or nitrocellulose membranes, which were then blocked with 5% milk for 1 hr at room temperature. Membranes were then probed with primary antibodies diluted in 1–5% milk or BSA for 3 hrs at room temperature or overnight at 4°C: rabbit anti-DYNC2LI1²⁶ (1:200; LIC3), rabbit anti-WDR34 (1:200; Abcam ab81030), rabbit anti-DYNC2H1²⁶ (1:150; Dynein HC2), rabbit anti-GAPDH (1:1,000; 14C10; Cell Signaling Technology #2118), mouse anti- β -tubulin (1:10,000; GTU-88; Abcam ab11316), mouse anti- β -tubulin (1:5000; Sigma T9026), and goat anti-GLI3 (1 $\mu\text{g mL}^{-1}$; R&D Systems AF3690). After extensive washing, membranes were incubated with HRP-conjugated or fluorescent secondary antibodies and the signal was captured on film or in an Odyssey system (Licor). Protein amounts were quantified from scanned blots using ImageJ (NIH). Full scans of Western blot data are included in Supplementary Fig. 6.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the families who participated in this study. This work is supported by NIH grants R01AR062651 to D.H.C, R01 AR066124 to D.K., R01 GM102347 and R01 HD40182 to R.B.V., P30 AR057230 to S.F.N, NIH Training Grant in Genomic Analysis and Interpretation T32 HG002536 to S.P.T. Sequencing was provided by the University of Washington Center for Mendelian Genomics (UW CMG) and was funded by the National Human Genome Research Institute and the National Heart, Lung and Blood Institute (Grant IU54 HG006493) to Drs. Debbie Nickerson, Jay Shendure, and Michael Bamshad. We also thank the March of Dimes and the Joseph Drown Foundation for their support. We are grateful to the CNSI Advanced Light Microscopy/Spectroscopy Shared Resource Facility at UCLA, supported with funding from NIH-NCRR shared resources grant (CJX1-443835-

WS-29646), and NSF Major Research Instrumentation grant (CHE-0722519), for their assistance. The research was also supported by NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant Number UL1TR000124 and by NIH/National Institute of Arthritis Musculoskeletal and Skin (NIAMS). We thank Iain Cheeseman for the hTERT-RPE1-GFP-CSAP cell line and Kathryn Anderson for the smoothed (SMO) antibody.

References

1. Berbari NF, O'Connor AK, Haycraft CJ, Yoder BK. The primary cilium as a complex signaling center. *Curr Biol*. 2009; 19:R526–535. [PubMed: 19602418]
2. Badano JL, Mitsuma N, Beales PL, Katsanis N. The ciliopathies: an emerging class of human genetic disorders. *Annu Rev Genomics Hum Genet*. 2006; 7:125–148. [PubMed: 16722803]
3. Kozminski KG, Johnson KA, Forscher P, Rosenbaum JL. A motility in the eukaryotic flagellum unrelated to flagellar beating. *Proc Natl Acad Sci USA*. 1993; 90:5519–5523. [PubMed: 8516294]
4. Dagoneau N, et al. DYNC2H1 mutations cause asphyxiating thoracic dystrophy and short rib-polydactyly syndrome, type III. *Am J Hum Genet*. 2009; 84:706–711. [PubMed: 19442771]
5. Baujat G, et al. Asphyxiating thoracic dysplasia: clinical and molecular review of 39 families. *J Med Genet*. 2013; 50:91–98. [PubMed: 23339108]
6. Beales PL, et al. IFT80, which encodes a conserved intraflagellar transport protein, is mutated in Jeune asphyxiating thoracic dystrophy. *Nat Genet*. 2007; 39:727–729. [PubMed: 17468754]
7. Cavalcanti DP, et al. Mutation in IFT80 in a fetus with the phenotype of Verma-Naumoff provides molecular evidence for Jeune-Verma-Naumoff dysplasia spectrum. *J Med Genet*. 2011; 48:88–92. [PubMed: 19648123]
8. Gilissen C, et al. Exome sequencing identifies WDR35 variants involved in Sensenbrenner syndrome. *Am J Hum Genet*. 2010; 87:418–423. [PubMed: 20817137]
9. Mill P, et al. Human and mouse mutations in WDR35 cause short-rib polydactyly syndromes due to abnormal ciliogenesis. *Am J Hum Genet*. 2011; 88:508–515. [PubMed: 21473986]
10. Bredrup C, et al. Ciliopathies with skeletal anomalies and renal insufficiency due to mutations in the IFT-A gene WDR19. *Am J Hum Genet*. 2011; 89:634–643. [PubMed: 22019273]
11. Thiel C, et al. NEK1 mutations cause short-rib polydactyly syndrome type majewski. *Am J Hum Genet*. 2011; 88:106–114. [PubMed: 21211617]
12. El Hokayem J, et al. NEK1 and DYNC2H1 are both involved in short rib polydactyly Majewski type but not in Beemer Langer cases. *J Med Genet*. 2012; 49:227–233. [PubMed: 22499340]
13. Huber C, et al. WDR34 mutations that cause short-rib polydactyly syndrome type III/severe asphyxiating thoracic dysplasia reveal a role for the NF-kappaB pathway in cilia. *Am J Hum Genet*. 2013; 93:926–931. [PubMed: 24183449]
14. Schmidts M, et al. Mutations in the gene encoding IFT dynein complex component WDR34 cause Jeune asphyxiating thoracic dystrophy. *Am J Hum Genet*. 2013; 93:932–944. [PubMed: 24183451]
15. Perrault I, et al. Mainzer-Saldino syndrome is a ciliopathy caused by IFT140 mutations. *Am J Hum Genet*. 2012; 90:864–870. [PubMed: 22503633]
16. Schmidts M, et al. Combined NGS approaches identify mutations in the intraflagellar transport gene IFT140 in skeletal ciliopathies with early progressive kidney disease. *Hum Mut*. 2013; 34:714–724. [PubMed: 23418020]
17. Halbritter J, et al. Defects in the IFT-B component IFT172 cause Jeune and Mainzer-Saldino syndromes in humans. *Am J Hum Genet*. 2013; 93:915–925. [PubMed: 24140113]
18. McInerney-Leo AM, et al. Short-rib polydactyly and Jeune syndromes are caused by mutations in WDR60. *Am J Hum Genet*. 2013; 93:515–523. [PubMed: 23910462]
19. Davis EE, et al. TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum. *Nat Genet*. 2011; 43:189–196.10.1038/ng.756 [PubMed: 21258341]
20. Asante D, Stevenson NL, Stephens DJ. Subunit composition of the human cytoplasmic dynein-2 complex. *J Cell Sci*. 2014; 127:4774–4787. [PubMed: 25205765]
21. Pazour GJ, Dickert BL, Witman GB. The DHC1b (DHC2) isoform of cytoplasmic dynein is required for flagellar assembly. *J Cell Biol*. 1999; 144:473–481. [PubMed: 9971742]

22. Porter ME, Bower R, Knott JA, Byrd P, Dentler W. Cytoplasmic dynein heavy chain 1b is required for flagellar assembly in *Chlamydomonas*. *Mol Biol Cell*. 1999; 10:693–712. [PubMed: 10069812]
23. Signor D, et al. Role of a class DHC1b dynein in retrograde transport of IFT motors and IFT raft particles along cilia, but not dendrites, in chemosensory neurons of living *Caenorhabditis elegans*. *The J Cell Biol*. 1999; 147:519–530. [PubMed: 10545497]
24. Rompolas P, Pedersen LB, Patel-King RS, King SM. *Chlamydomonas* FAP133 is a dynein intermediate chain associated with the retrograde intraflagellar transport motor. *J Cell Sci*. 2007; 120:3653–3665. [PubMed: 17895364]
25. Patel-King RS, Gilberti RM, Hom EF, King SM. WD60/FAP163 is a dynein intermediate chain required for retrograde intraflagellar transport in cilia. *Mol Biol Cell*. 2013; 24:2668–2677. [PubMed: 23864713]
26. Mikami A, et al. Molecular structure of cytoplasmic dynein 2 and its distribution in neuronal and ciliated cells. *J Cell Sci*. 2002; 115:4801–4808. [PubMed: 12432068]
27. Perrone CA, et al. A novel dynein light intermediate chain colocalizes with the retrograde motor for intraflagellar transport at sites of axoneme assembly in *Chlamydomonas* and mammalian cells. *Mol Biol Cell*. 2003; 14:2041–2056. [PubMed: 12802074]
28. Schafer JC, Haycraft CJ, Thomas JH, Yoder BK, Swoboda P. XBX-1 encodes a dynein light intermediate chain required for retrograde intraflagellar transport and cilia assembly in *Caenorhabditis elegans*. *Mol Biol Cell*. 2003; 14:2057–2070. [PubMed: 12802075]
29. Hou Y, Pazour GJ, Witman GB. A dynein light intermediate chain, D1bLIC, is required for retrograde intraflagellar transport. *Mol Biol Cell*. 2004; 15:4382–4394. [PubMed: 15269286]
30. Pazour GJ, Wilkerson CG, Witman GB. A dynein light chain is essential for the retrograde particle movement of intraflagellar transport (IFT). *J Cell Biol*. 1998; 141:979–992. [PubMed: 9585416]
31. Grissom PM, Vaisberg EA, McIntosh JR. Identification of a novel light intermediate chain (D2LIC) for mammalian cytoplasmic dynein 2. *Mol Biol Cell*. 2002; 13:817–829. [PubMed: 11907264]
32. Efimenko E, et al. Analysis of *xbx* genes in *C. elegans*. *Development*. 2005; 132:1923–1934. [PubMed: 15790967]
33. Engel BD, et al. The role of retrograde intraflagellar transport in flagellar assembly, maintenance, and function. *The J Cell Biol*. 2012; 199:151–167. [PubMed: 23027906]
34. Blisnick T, et al. The intraflagellar transport dynein complex of trypanosomes is made of a heterodimer of dynein heavy chains and of light and intermediate chains of distinct functions. *Mol Biol Cell*. 2014; 25:2620–2633. [PubMed: 24989795]
35. Rana AA, et al. Targeted deletion of the novel cytoplasmic dynein mD2LIC disrupts the embryonic organizer, formation of the body axes and specification of ventral cell fates. *Development*. 2004; 131:4999–5007. [PubMed: 15371312]
36. Merrill AE, et al. Ciliary abnormalities due to defects in the retrograde transport protein DYNC2H1 in short-rib polydactyly syndrome. *Am J Hum Genet*. 2009; 84:542–549. [PubMed: 19361615]
37. Tynan SH, Purohit A, Doxsey SJ, Vallee RB. Light intermediate chain 1 defines a functional subfraction of cytoplasmic dynein which binds to pericentrin. *J Biol Chem*. 2000; 275:32763–32768. [PubMed: 10893222]
38. Tan SC, Scherer J, Vallee RB. Recruitment of dynein to late endosomes and lysosomes through light intermediate chains. *Mol Biol Cell*. 2011; 22:467–477. [PubMed: 21169557]
39. Taulman PD, Haycraft CJ, Balkovetz DF, Yoder BK. Polaris, a protein involved in left-right axis patterning, localizes to basal bodies and cilia. *Mol Biol Cell*. 2001; 12:589–599. [PubMed: 11251073]
40. Murdoch JN, Copp AJ. The relationship between sonic Hedgehog signaling, cilia, and neural tube defects. *Birth Defects Res A*. 2010; 88:633–652.
41. Ocbina PJ, Eggenschwiler JT, Moskowitz I, Anderson KV. Complex interactions between genes controlling trafficking in primary cilia. *Nat Genet*. 2011; 43:547–553. [PubMed: 21552265]

42. Wang B, Fallon JF, Beachy PA. Hedgehog-regulated processing of Gli3 produces an anterior/posterior repressor gradient in the developing vertebrate limb. *Cell*. 2000; 100:423–434. [PubMed: 10693759]
43. Liem KF Jr, et al. The IFT-A complex regulates Shh signaling through cilia structure and membrane protein trafficking. *The J Cell Biol*. 2012; 197:789–800. [PubMed: 22689656]
44. Chaya T, Omori Y, Kuwahara R, Furukawa T. ICK is essential for cell type-specific ciliogenesis and the regulation of ciliary transport. *EMBO J*. 2014; 33:1227–1242. [PubMed: 24797473]
45. Asai DJ, Rajagopalan V, Wilkes DE. Dynein-2 and ciliogenesis in Tetrahymena. *Cell Motil Cytoskel*. 2009; 66:673–677.
46. Huangfu D, Anderson KV. Cilia and Hedgehog responsiveness in the mouse. *Proc Natl Acad Sci USA*. 2005; 102:11325–11330. [PubMed: 16061793]
47. Kronenberg HM. The role of the perichondrium in fetal bone development. *Ann NY Acad Sci*. 2007; 1116:59–64. [PubMed: 18083921]
48. Touaitahuata H, Cres G, de Rossi S, Vives V, Blangy A. The mineral dissolution function of osteoclasts is dispensable for hypertrophic cartilage degradation during long bone development and growth. *Dev Biol*. 2014; 393:57–70. [PubMed: 24992711]
49. McKenna A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res*. 2010; 20:1297–1303. [PubMed: 20644199]
50. DePristo MA, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet*. 2011; 43:491–498. [PubMed: 21478889]
51. Van der Auwera GA, et al. From FastQ Data to High-Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline. *Curr Protoc Bioinformatics*. 2013; 11:11.10.11–11.10.33. [PubMed: 25431634]
52. Yourshaw M, Taylor SP, Rao AR, Martin MG, Nelson SF. Rich annotation of DNA sequencing variants by leveraging the Ensembl Variant Effect Predictor with plugins. *Brief Bioinform*. 2014; 1093/bib/bbu008
53. Adzhubei IA, et al. A method and server for predicting damaging missense mutations. *Nat Methods*. 2010; 7:248–249. [PubMed: 20354512]
54. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc*. 2009; 4:1073–1081. [PubMed: 19561590]
55. Gonzalez-Perez A, Lopez-Bigas N. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score. *Condel. Am J Hum Genet*. 2011; 88:440–449. [PubMed: 21457909]
56. Kircher M, et al. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet*. 2014; 46:310–315. [PubMed: 24487276]
57. Backer CB, Gutzman JH, Pearson CG, Cheeseman IM. CSAP localizes to polyglutamylated microtubules and promotes proper cilia function and zebrafish development. *Mol Biol Cell*. 2012; 23:2122–2130. [PubMed: 22493317]
58. Edde B, et al. Posttranslational glutamylation of alpha-tubulin. *Science*. 1990; 247:83–85. [PubMed: 1967194]





Figure 1. Mutations in *DYNC2LI1* cause short rib polydactyly syndrome. Radiographs of the affected probands, R03-303A, R01-013A and R07-628A (International Skeletal Dysplasia Registry reference numbers) showing short long bones, horizontal ribs and long narrow chest, poor mineralization of some skeletal elements (single arrow), metaphyseal irregularity (double arrows), and polydactyly in all the limbs of the affected individuals.

**Figure 2.**

Effect of *DYNC2LI1* mutations on splicing and protein stability. (a) RT-PCR of cDNA derived from control and SRPS fibroblasts shows that *DYNC2LI1* splice-donor mutations cause in-frame skipping of exon 12. (b) Immunoblotting reveals significant reduction in the amounts of DYNC2LI1 from lysates of affected cells compared with control. Size markers (right, kDa), β -tubulin, loading control. (c) Quantification of average DYNC2LI1 amounts from (b) for each genotype. Values were normalized to control and error bars represent \pm

s.e.m (3 independent experiments). Statistical analyses performed using the Mann-Whitney test, $p < 0.05$ labeled with *.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript






Figure 3. Mutations in *DYNC2L1* decrease the stability of DYNC2H1. (a) Immunoblotting for components of the dynein-2 complex (heavy chain, DYNC2H1; intermediate chain, WDR34) and the heavy chain of the dynein-1 complex (DYNC1H1) reveals a specific reduction of DYNC2H1. (b) Immunofluorescence micrographs of control and SRPS cells stained for GluTUB (red) and WDR34 (green) or DYNC2H1 (green). Cilia (2x) are shown on the right. Scale bar = 5 μ m.

**Figure 4.**

Components of the dynein-2 complex are co-expressed in a human cartilage growth plate. (a) Sections from a 14-week human humerus were stained for DYNC2LI1, DYNC2H1 and WDR34. All three proteins were expressed in the perichondrium/periosteum and primary spongiosa (closed arrows, perichondrium/periosteum; open arrows, primary spongiosa). Scale bar = 50 μ m.

**Figure 5.**

Primary cilia are variable in length and longer in *DYNC2LI1*-mutant cells. (a) Immunofluorescence micrographs of serum-starved control and SRPS fibroblasts stained for ARL13B (green), GluTUB (red) and Hoescht (blue) show variable length and hyperelongated cilia in SRPS cells. (b) Percentage of ciliated cells in (a) (n=150 X 3 independent experiments). (c) Primary cilium length is highly variable in cells with *DYNC2LI1* mutations (n>20 X 3 independent experiments). (d) Expression of untagged wild type *DYNC2LI1* through an IRES-GFP vector (artificially colored blue) rescues cilia length variability in SRPS cells. Error bars represent \pm s.e.m. Statistical analyses performed using Mann-Whitney test, $p < 0.05$ values labeled with *. Scale bar = 5 μ m.




Figure 6. *DYNC2L1* mutations delay retrograde IFT and lead to the ciliary accumulation of IFT components. (a) Immunofluorescence micrographs of control and SRPS cells stained as labeled. Cilia (2x) are shown on the right. (b) Expression of untagged wild type *DYNC2L1* through an IRES-GFP vector (artificially colored blue) rescues ciliary accumulation of IFT components. (c) Quantification of IFT88 signal: graph shows the mean ratio of IFT88 signal between the cilium body and its proximal end \pm s.e.m (n=20 X 3 independent experiments). Statistical analyses performed using Mann-Whitney test, p<0.05 values labeled with *. Scale bar = 5 μ m.




Figure 7. Disruption of the dynein-2 complex leads to aberrant Hedgehog signaling. (a) Immunofluorescence micrographs of control and SRPS cells treated with SAG and stained for GLI3 (red), AcTUB (green), and DAPI (blue). (b) *DYNC2L1*/dynein-2 complex activity is required for the exclusion of SMO from the primary cilium in the absence of Hedgehog stimulation. Immunofluorescence micrographs of SAG-stimulated control and SRPS cells stained for SMO (green) and GluTUB (red). (c) Graph shows the mean percentage of ciliated cells with ciliary SMO ± s.e.m. (>100 cells counted X 3 independent experiments). (d) Immunoblotting for GLI3 (full length “GLI3FL”; repressor “GLI3R”) in cell extracts shows increased GLI3FL to GLI3R in SRPS cells. (e) Graph shows the ratio of GLI3FL to GLI3R. (f) Graph shows quantification of total GLI3 amounts (GLI3FL + GLI3R) which is increased in *DYNC2L1*-mutant fibroblasts. Statistical analyses performed using Mann-Whitney test, $p < 0.05$ is labeled with *. Scale bars = 5 μ m.

Table 1

Pathogenic *DYNC2LI1* Mutations in SRPS Cohort

Sample ID	Genotype	Mutation	Location	Cons.*	Sift	Polyphen	CADD†	rsID	AF‡
R01-013A	0/1	c.993+1G>A	Intron 12	4.37			16.1		0.00008
	0/1	c.349C>G p.Leu117Val	Exon 6	3.63	deleterious	probably damaging	18.6	rs201948500	0.00023
R07-628A	0/1	c.349C>G p.Leu117Val	Exon 6	3.63	deleterious	probably damaging	18.6	rs201948500	0.00023
	0/1	c.372G>A p.Trp124Ter	Exon 6	4.46			26.5		
R03-303A	0/1	c.1000G>T p.Glu334Ter	Exon 13	4.55			38.0		
	0/1	c.993+3A>G	Intron 12	4.37			10.8		

* Conservation;

† Phred-scaled CADD score;

‡ mutant allele frequency